Reed Jobs would rather talk about curing cancer than his last name

Yosemite, a venture firm profiled at TechCrunch Disrupt, has expanded from a newly formed setup to a 17-person team, reflecting rapid scaling. Jobs says a wave of blockbuster biotech drugs losing patent protection in the same window is opening new opportunities, while AI has become a major part of Yosemite’s investment focus.

Analysis

The investable signal is not the venture firm’s growth; it is that a synchronized patent-expiry window tends to force big pharma back into external innovation at the same time, which lifts the odds of a deal wave and supports valuations for late-stage biotech with real data, while punishing incumbents that have not rebuilt pipelines. In public markets, that usually shows up first as dispersion: higher M&A optionality for small/mid-cap biotech, but pressure on large-cap pharma multiples if the market believes replacement revenue has to be bought rather than invented internally.

AI should be viewed as a productivity lever before it is a revenue model. The near-term winners are the infrastructure and workflow layers that biotech must buy regardless of whether the underlying drug thesis works — compute, cloud, lab automation, sequencing, and trial-management tooling — while pure-play AI-drug discovery names still face the same wet-lab and regulatory bottlenecks. If AI shortens hit rates or preclinical cycles, the second-order loser is the service model that monetizes complexity and delay, not the companies selling the picks-and-shovels.

The contrarian miss is that investors often overrate how quickly “AI in biotech” turns into realizable cash flows. Most of the value capture will likely accrue to platform owners and capital allocators, while venture-backed discovery companies remain binary and funding-sensitive; that argues for selectivity, not blanket enthusiasm. Watch for concrete catalysts over 1-3 months in licensing and M&A, but the structural read-through is 6-18 months: the best biotech franchises will be the ones that can turn AI into validated clinical assets, not just cheaper hypotheses.

Key Decisions for Investors

• No immediate directional trade on the article alone; treat this as a watch item until there is evidence of actual biotech M&A or licensing acceleration. Falsifier: if deal volume stays muted for 1-2 quarters, the patent-cliff read-through is overestimated.
• If acquisition activity picks up, go long XBI vs. short PFE or BMY over 1-3 months to express takeout optionality and pipeline scarcity. Risk/reward improves if 2+ large pharma names explicitly raise external-innovation budgets.
• Long NVDA as a secondary beneficiary of AI adoption in biotech on any broad tech pullback; the thesis is infrastructure demand, not drug-discovery hype. Falsify if biotech AI spend fails to show up in cloud/GPU utilization or enterprise guidance over the next 2 quarters.
• Avoid chasing pure-play AI-drug discovery startups; if you want exposure, prefer the enabling layer such as MSFT, AMZN, TMO, or IQV on evidence that AI is driving workflow adoption rather than clinical breakthroughs.